These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 26115094

  • 1. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY, Wang YY, Cai JQ, Zhang CB, Wang KY, Cheng W, Liu YW, Zhang W, Jiang T.
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [Abstract] [Full Text] [Related]

  • 2. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.
    Neurology; 2013 Oct 22; 81(17):1515-22. PubMed ID: 24068788
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.
    World J Surg Oncol; 2013 Oct 25; 11():284. PubMed ID: 24160898
    [Abstract] [Full Text] [Related]

  • 4. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS, Kwon MJ, Song JH, Kim ES, Kim HY, Min KW.
    Pathol Res Pract; 2018 Jun 25; 214(6):881-888. PubMed ID: 29650441
    [Abstract] [Full Text] [Related]

  • 5. Unveiling hierarchy and spatial distribution of O6-methylguanine-DNA methyltransferase promoter methylation in World Health Organization grade 2-3 gliomas.
    Li M, Liu J, Weng J, Dong G, Chen X, Cui Y, Ren X, Shen S, Jiang H, Zhang X, Zhao X, Li M, Wang X, Ren H, Li Q, Zhang Y, Cheng Q, Yu Y, Lin S.
    Cancer Sci; 2024 Oct 25; 115(10):3403-3414. PubMed ID: 39101880
    [Abstract] [Full Text] [Related]

  • 6. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.
    J Clin Oncol; 2009 Dec 10; 27(35):5874-80. PubMed ID: 19901110
    [Abstract] [Full Text] [Related]

  • 7. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P, Suri V, Jain A, Sharma MC, Pathak P, Jha P, Srivastava A, Suri A, Gupta D, Chosdol K, Chattopadhyay P, Sarkar C.
    Neurosurgery; 2010 Dec 10; 67(6):1681-91. PubMed ID: 21107199
    [Abstract] [Full Text] [Related]

  • 8. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.
    J Clin Oncol; 2009 Sep 01; 27(25):4150-4. PubMed ID: 19636000
    [Abstract] [Full Text] [Related]

  • 9. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J, Yang JH, Quan J, Kang X, Wang HJ, Dai PG.
    Tumour Biol; 2016 Oct 01; 37(10):13571-13579. PubMed ID: 27468718
    [Abstract] [Full Text] [Related]

  • 10. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T.
    J Neurooncol; 2016 Sep 01; 129(3):505-514. PubMed ID: 27401154
    [Abstract] [Full Text] [Related]

  • 11. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.
    J Neurooncol; 2012 May 01; 107(3):617-31. PubMed ID: 22287028
    [Abstract] [Full Text] [Related]

  • 12. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
    Ang SYL, Lee L, See AAQ, Ang TY, Ang BT, King NKK.
    BMC Cancer; 2020 Jan 31; 20(1):79. PubMed ID: 32005184
    [Abstract] [Full Text] [Related]

  • 13. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M, Drábek J, Dwight Z, Trojanec R, Koudeláková V, Vrbková J, Kalita O, Mlcochova S, Rabcanova M, Hajdúch M.
    Klin Onkol; 2017 Jan 31; 30(5):361-371. PubMed ID: 29031038
    [Abstract] [Full Text] [Related]

  • 14. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
    Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G.
    Acta Neuropathol; 2016 Feb 31; 131(2):309-319. PubMed ID: 26493382
    [Abstract] [Full Text] [Related]

  • 15. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H.
    Neurosurg Focus; 2015 Mar 31; 38(3):E2. PubMed ID: 25727224
    [Abstract] [Full Text] [Related]

  • 16. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
    Roszkowski K, Furtak J, Zurawski B, Szylberg T, Lewandowska MA.
    Int J Mol Sci; 2016 Nov 10; 17(11):. PubMed ID: 27834917
    [Abstract] [Full Text] [Related]

  • 17. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.
    J Clin Oncol; 2009 Dec 01; 27(34):5743-50. PubMed ID: 19805672
    [Abstract] [Full Text] [Related]

  • 18. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
    Li MY, Yang P, Liu YW, Zhang CB, Wang KY, Wang YY, Yao K, Zhang W, Qiu XG, Li WB, Peng XX, Wang YZ, Jiang T.
    Sci Rep; 2016 Feb 16; 6():21141. PubMed ID: 26879272
    [Abstract] [Full Text] [Related]

  • 19. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W.
    Neuro Oncol; 2014 Dec 16; 16(12):1630-8. PubMed ID: 25028501
    [Abstract] [Full Text] [Related]

  • 20. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
    Kinslow CJ, Mercurio A, Kumar P, Rae AI, Siegelin MD, Grinband J, Taparra K, Upadhyayula PS, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Kachnic LA, Yu JB, Cheng SK, Wang TJC.
    JAMA Oncol; 2023 Jul 01; 9(7):919-927. PubMed ID: 37200021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.